Syndax Pharmaceuticals (SNDX) Retained Earnings (2015 - 2026)

Syndax Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 18.63% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 18.63% YoY), while the FY2025 annual figure was -$1.5 billion, down 23.37% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$1.5 billion in the prior quarter.
• The five-year high for Retained Earnings was -$580.9 million in Q1 2022, with the low at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$974.8 million (2024), against an average of -$1.0 billion.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings climbed 2.6% in 2022, then slumped 35.79% in 2024.
• Syndax Pharmaceuticals' Retained Earnings stood at -$693.0 million in 2022, then tumbled by 30.21% to -$902.4 million in 2023, then sank by 35.32% to -$1.2 billion in 2024, then declined by 23.37% to -$1.5 billion in 2025, then fell by 2.83% to -$1.5 billion in 2026.
• Business Quant data shows SNDX's Retained Earnings at -$1.5 billion in Q1 2026, -$1.5 billion in Q4 2025, and -$1.4 billion in Q3 2025.